ROYALTY PHARMA PLC- CL A (RPRX)

GB00BMVP7Y09 - Common Stock

24.92  +0.64 (+2.64%)

After market: 25.01 +0.09 (+0.36%)

Full estimates are only available for subscribed users, you can see which data is available below.

Subscribed users also see more surprise data, now it is restricted to 4 quarters.

Examples of complete estimate data are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional estimates and surprises .

Yearly Revenue, EBIT, EBITDA and EPS Analyst Estimates
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031
Revenue
YoY % growth
2.29B
7.87%
2.237B
-2.28%
2.355B
5.25%
2.642B
12.21%
2.936B
11.13%
3.247B
10.59%
2.751B
-15.28%
2.882B
4.76%
2.989B
3.71%
3.086B
3.25%
3.221B
4.37%
EBITDA
YoY % growth
N/A
20.16%
N/A
31.88%
N/A
7.26%
2.43B
-12.93%
2.707B
11.40%
2.917B
7.76%
3.602B
23.48%
3.976B
10.38%
4.229B
6.36%
4.456B
5.37%
4.621B
3.70%
EBIT
YoY % growth
1.431B
-13.84%
922.9M
-35.49%
1.492B
61.68%
2B
34.03%
2.298B
14.90%
2.409B
4.83%
2.306B
-4.28%
2.406B
4.34%
2.474B
2.83%
2.544B
2.83%
2.655B
4.36%
Operating Margin
62.49%41.25%63.37%75.70%78.27%74.19%83.82%83.48%82.77%82.44%82.43%
EPS
YoY % growth
2.23
-10.34%
3.67
64.57%
4.38
19.35%
4.03
-7.89%
4.46
10.62%
4.92
10.15%
6.18
25.73%
7.06
14.19%
7.29
3.32%
7.52
3.08%
N/A

All data in USD

Quarterly Revenue, EBIT, EBITDA and EPS Analyst Estimates
Q4 / 24 Q1 / 25 Q2 / 25 Q3 / 25 Q4 / 25
EPS
Q2Q % growth
1.01
-12.34%
1.07
9.63%
1.13
17.23%
1.08
7.05%
1.39
37.61%
Revenue
Q2Q % growth
603.84M
1.32%
706.37M
24.36%
690.23M
13.52%
733.8M
29.88%
N/A
EBITDA
Q2Q % growth
586.18M
-9.70%
704.62M
8.35%
622.2M
6.78%
686.21M
4.25%
803.76M
37.12%
EBIT
Q2Q % growth
520.71M
-15.04%
375.33M
608.76%
359.26M
33.24%
678.67M
-7.67%
N/A

All data in USD

Recent Earnings VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
1.01
27.85%
0.950.066.65%
Q2 2024
Q2Q % growth
0.96
14.29%
0.98-0.02-2.47%
Q1 2024
Q2Q % growth
0.98
-38.75%
1.00-0.02-2.16%
Q4 2023
Q2Q % growth
1.15
-26.28%
1.030.1211.63%
Q3 2023
Q2Q % growth
0.79
9.72%
0.770.022.45%
Q2 2023
Q2Q % growth
0.84
6.33%
0.820.021.92%
Q1 2023
Q2Q % growth
1.60
166.67%
1.300.3023.19%
Q4 2022
Q2Q % growth
1.56
95.00%
1.500.063.86%
Q3 2022
Q2Q % growth
0.72
323.53%
0.73-0.01-1.45%
Q2 2022
Q2Q % growth
0.79
-26.85%
0.80-0.01-0.86%
Q1 2022
Q2Q % growth
0.60
233.33%
0.75-0.15-19.60%
Q4 2021
Q2Q % growth
0.80
185.71%
0.790.011.20%
Q3 2021
Q2Q % growth
0.17
-64.58%
0.71-0.54-75.92%
Q2 2021
Q2Q % growth
1.08
47.95%
0.710.3752.35%
Q1 2021
Q2Q % growth
0.18 0.66-0.48-72.85%
Q4 2020
Q2Q % growth
0.28 0.71-0.43-60.46%
Q3 2020
Q2Q % growth
0.48 0.60-0.12-20.46%
Q2 2020
Q2Q % growth
0.73 0.620.1117.60%
Recent Revenue VS Estimates Surprises (USD)
PeriodReportedEstimateDifferenceSurprise
Q3 2024
Q2Q % growth
565M
5.35%
710.02M-145.02M-20.42%
Q2 2024
Q2Q % growth
608M
13.01%
641.1M-33.1M-5.16%
Q1 2024
Q2Q % growth
568M
-16.96%
676.48M-108.48M-16.04%
Q4 2023
Q2Q % growth
596M
5.36%
705.48M-109.48M-15.52%
Q3 2023
Q2Q % growth
536.313M
-6.48%
630.35M-94.037M-14.92%
Q2 2023
Q2Q % growth
538M
0.37%
547.32M-9.32M-1.70%
Q1 2023
Q2Q % growth
684M
21.71%
869.96M-185.96M-21.38%
Q4 2022
Q2Q % growth
565.7M
-1.74%
970.32M-404.62M-41.70%
Q3 2022
Q2Q % growth
573.5M
-2.10%
598.92M-25.42M-4.24%
Q2 2022
Q2Q % growth
536M
-3.42%
553.02M-17.02M-3.08%
Q1 2022
Q2Q % growth
562M
-1.92%
611.75M-49.75M-8.13%
Q4 2021
Q2Q % growth
575.7M
0.63%
567.42M8.28M1.46%
Q3 2021
Q2Q % growth
585.8M
8.80%
584.26M1.54M0.26%
Q2 2021
Q2Q % growth
555M
8.63%
528.25M26.75M5.06%
Q1 2021
Q2Q % growth
573M
14.39%
519.89M53.11M10.22%
Q4 2020
Q2Q % growth
572.1M
25.05%
490.33M81.77M16.68%
Q3 2020
Q2Q % growth
538.4M
15.96%
462.23M76.17M16.48%
Q2 2020
Q2Q % growth
510.9M
11.65%
478.34M32.56M6.81%
Q1 2020
Q2Q % growth
500.9M
15.18%
%
EPS and Revenue Revisions
Next Q (1 month) Next Q (3 month) Next Year (1 month) Next Year (3 month)
EPS0% -6.47% 0.58% 0.69%
Revenue2.67% -6.22% -0.15% -1.71%